ClinicalTrials.gg
Not yet recruitingNCT07940751SORTUpdated Nov 17, 2026

Screening fOR Throat Cancer

An observational study in Oropharyngeal Cancer and Human Papillomavirus, sponsored by Johns Hopkins University. Not yet recruiting at 1 site in United States. Open to male participants aged 40 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Johns Hopkins University · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
40 Years to 69 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 235 studies in Oropharyngeal Neoplasms with a site in United States — 63 open to participants now, 98 under way, 11 of them phase 3. Oropharyngeal Neoplasms · United States.

Planned enrollment
2nd of 36
2,500 · median 205
Started
2027
with 3 others
Observational
36 of 235
9 open now
Primary completion
2032-01
later than 92 of 97 live
Registered
235th of 235
by date

Among the 235 studies in Oropharyngeal Neoplasms with a site in United States, this one is the 2nd largest by planned enrollment of the 36 observational ones that give a count, is one of 4 that started in 2027, is one of 36 observational ones, reaches primary completion later than 92 of the 97 other live ones, and was the 235th registered.

Oropharyngeal Neoplasms

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

Browse Oropharyngeal Neoplasms studies →

Open to participants now

63 of the 235 studies in Oropharyngeal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 40 Years to 69 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 235 studies in Oropharyngeal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will screen people for biomarkers of Human Papillomavirus (HPV) to form a cohort of people who may be at increased risk of HPV-oropharyngeal cancer (HPV-OPC). The investigators will follow these individuals prospectively to evaluate risk for OPC.

Read the detailed description

This study will assess HPV16 biomarkers, including serum HPV16 E6 antibodies, plasma and oral HPV16 DNA, and ultrasound, to understand the feasibility and utility of HPV16 biomarker screening to identify those at increased risk of HPV-OPC. This study will screen approximately 2500 people. The focus of the study is to determine whether sequential testing for oral and plasma HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies among people with and without HIV. The study includes community screening, as well as biobank screening with longitudinal follow-up of those who screen positive.

Study Design Overview: This study has an initial screen that includes two populations: screening of biobank samples "biobank group" and screening of healthy members of the community "community group" which can be done via an in-person visit or via remote sample collection. The subset of participants with HPV16 biomarkers detected will be asked to join the longitudinal follow-up. During follow-up, participants will have more samples collected and have a neck ultrasound to look for any precancerous lesions.

The study is led by Dr. Amber D'Souza and Dr. Carole Fakhry (Johns Hopkins). Participants are being enrolled from the MWCCS cohort, from Baltimore, MD, and across the US. If interested, complete the study eligibility form at [link coming] or email hpv@jhu.edu with questions.

03

Conditions studied

  • Oropharyngeal Cancer
  • Human Papillomavirus

Keywords

  • Oral HPV
  • Persistent infection
  • Oropharyngeal cancer (OPC)
  • HPV antibody
  • HPV Screening Study
  • Sequential HPV testing
04

Who can participate

Ages eligible
40 Years to 69 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will be drawn from multiple sources, including healthy men from the broader U.S. population interested in the study via online self-referral, website outreach, or study outreach, as well as participants from the MACS WIHS Combined Cohort Study (MWCCS).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part I: Participants in Screening

To be eligible to participate in Part I of this study, an individual must meet the following criteria:

Community and Internet Screen eligibility:

  • Male, 40-69 years old
  • Willing to self-collect or come in person to collect screening biospecimens
  • Willing to be contacted to arrange follow-up visits, if determined to be eligible for follow-up
  • Ability to understand and the willingness to sign a written document

Biorepository Screen eligibility:

  • Male, 40-69 years old
  • Active participant within MWCCS
  • Willing to be contacted to arrange follow-up visits, if determined to be eligible for follow-up
  • Ability to understand and the willingness to sign a written informed consent document

    • Part II: Participants in Follow-Up

To be eligible to participate in Part II of this study, an individual must meet all of the following criteria:

  • HPV16 biomarker detected in Part I screen
  • Willingness to complete annual follow-up visits

Exclusion criteria

Exclusion Criteria:

  • Part I: Participants in Screening

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Presence of medical or psychiatric condition affecting ability to give voluntary, .
  • Participants who do not speak English cannot enroll because the consent and study survey are only available in English. However, if there is a hearing, literacy, or minor fluency issue and the participant requests assistance from a family member or the study coordinator, this individual may still enroll and receive this assistance to ensure the participant fully hears and understands everything being asked.
  • History of head and neck cancer

    • Part II: Participants in Follow-Up

An individual who meets any of the following criteria will be excluded from participation in this part of the study:

  • Unable to complete annual follow-up visits
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Prospective Observational Cohort

    Prospective cohort of adult male participants from two groups: community group (see eligibility form) an biobank group (enrolled from MWCCS cohort). Both groups will undergo initial screening, with eligible participants continuing onto follow-up testing, which may include blood collection, oral rinse collection, anal Pap smear, ultrasound imaging, and surveys.

06

What researchers measure

Primary outcomes

  1. HPV16 E6 antibodies present or absent in serum sample

    To determine whether sequential testing for oral or plasma HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies.

    Time frame: Baseline to end of three-year follow-up

  2. Oral HPV16 DNA present or absent

    To determine whether sequential testing for oral HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies.

    Time frame: Baseline to end of three-year follow-up

Secondary outcomes

  1. Feasibility of community screening

    To assess whether primary screening in a community setting of healthy individuals can lead to at least 80% of those with HPV16 E6 antibodies identified agreeing to complete follow-up biomarker collection and ultrasound for secondary screening.

    Time frame: Baseline to end of three-year follow-up

07

Study locations

1 site
  • Johns Hopkins Hospital
    Baltimore, Maryland 21205, United States
    • Amber D'Souza, PhD · Contactgdsouza2@jhu.edu · 410-502-2583
    • Amber D'Souza, PhD · Principal investigator
    • Carole Fakhry, MD, MPH · Principal investigator
08

References and documents

Publications

  • D'Souza G, Tewari SR, Troy T, Waterboer T, Struijk L, Castillo R, Wright H, Shen M, Miles B, Johansson M, Robbins HA, Fakhry C. Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results of the MOUTH study. Cancer. 2023 Aug 1;129(15):2373-2384. doi: 10.1002/cncr.34783. Epub 2023 Apr 9. PubMed 37032449 ↗
  • Scott-Wittenborn N, D'Souza G, Tewari S, Rooper L, Troy T, Drake V, Bigelow EO, Windon MJ, Ryan WR, Ha PK, Kiess AP, Miles B, Westra WH, Mydlarz WK, Eisele DW, Fakhry C. Prevalence of human papillomavirus in head and neck cancers at tertiary care centers in the United States over time. Cancer. 2022 May 1;128(9):1767-1774. doi: 10.1002/cncr.34124. Epub 2022 Feb 8. PubMed 35132635 ↗
  • Scott-Wittenborn N, D'Souza G, Aygun N, Tewari SR, Azadi J, Vosler P, Gooi Z, Mehta V, Mydlarz W, Nance M, Mlot S, Patel MR, Tan M, Miles BA, Troy T, Fakhry C. Feasibility of clinical evaluation of individuals with increased risk for HPV-associated oropharynx cancer. Head Neck. 2023 Jan;45(1):95-102. doi: 10.1002/hed.27212. Epub 2022 Oct 6. PubMed 36200696 ↗
  • Tewari SR, D'Souza G, Troy T, Wright H, Struijk L, Waterboer T, Fakhry C. Association of Plasma Circulating Tumor HPV DNA With HPV-Related Oropharynx Cancer. JAMA Otolaryngol Head Neck Surg. 2022 May 1;148(5):488-489. doi: 10.1001/jamaoto.2022.0159. PubMed 35323891 ↗
  • D'Souza G, Tewari SR, Troy T, Webster-Cyriaque J, Wiley DJ, Lahiri CD, Palella FJ, Gillison ML, Strickler HD, Struijk L, Waterboer T, Ho K, Kwait J, Lazar J, Weber KM, Fakhry C. Oncogenic Oral Human Papillomavirus Clearance Patterns over 10 Years. Cancer Epidemiol Biomarkers Prev. 2024 Apr 3;33(4):516-524. doi: 10.1158/1055-9965.EPI-23-1272. PubMed 38294704 ↗
  • DSouza G, Tewari S, Troy T, Bleyer P, Korley M, Kwait J, Ho K, Gillison M, Wiley D, Lazar J, Weber KM, Strickler H, Lahiri CD, Palella F, Struijk L, Fakhry C. Oral HPV incidence and risk factors for acquisition. Oral Oncol. 2025 Apr;163:107249. doi: 10.1016/j.oraloncology.2025.107249. Epub 2025 Mar 17. PubMed 40101427 ↗

Individual participant data

Plan to share: Yes — The investigators will utilize a plan for the controlled release, management, and sharing of data. Data will be made available through a study research proposal process.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2032, 60 months later.

Of 47 observational studies under Oropharyngeal Neoplasms, half reached primary completion within 110 months of starting (the median), counting those still running; a quarter within 40. This study's planned 60 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Jan 2027
Primary completionEst.
Jan 2032
CompletionEst.
Jan 2037
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940751
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2032 (estimated)
Completion
Jan 2037 (estimated)
Last update
Nov 17, 2026

Study contacts

Amber D'Souza, PhD
Contact
gdsouza2@jhu.edu
410-502-2583

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion